illumiSonics Inc. Welcomes James Tweel as Principal Research Scientist

March 18, 2026 - illumiSonics Inc., a leading innovator in advanced biomedical imaging technologies, is pleased to announce the appointment of James Tweel as Principal Research Scientist.

Dr. Tweel brings extensive expertise in biomedical imaging and has played a critical role in the development of the company’s core technologies, PARS® (Photon Absorption Remote Sensing) and MLI® (Multi-Laser Imaging), which serve as central pillars of illumiSonics’ proprietary imaging platform. His work has focused on advancing label-free histological imaging and deep learning-based virtual staining, contributing to more than 8 peer-reviewed publications and 3 patents related to PARS and MLI® to date.

“We are excited to have James join our team,” said John Mackey, CEO of illumiSonics Inc. “He has been a key contributor to the evolution of PARS and MLI® from the early stages, and his deep technical knowledge will be invaluable as we enter our next phase of innovation and commercialization.”

Dr. Tweel recently completed his Ph.D. in Systems Design Engineering at the University of Waterloo. His thesis, “Developments in Photon Absorption Remote Sensing Microscopy and Deep Learning–Based Virtual Histochemical Staining,” introduced a label-free histology framework combining PARS microscopy with deep learning to generate multi-stain virtual histology images without chemical processing, and helped lay the groundwork for many of the advances now embedded in illumiSonics’ imaging systems.

“Joining illumiSonics at this stage is exciting because it’s where deep technical work meets real clinical impact,” said Dr. Tweel. “I’ve been closely involved in developing PARS and MLI®, and I’m looking forward to continuing to push the technology toward robust, high-throughput imaging for real-world pathology and research applications.”

About illumiSonics Inc. illumiSonics Inc. is a Waterloo, Ontario based company that has developed the MLI® (Multi-Laser Imaging) platform: a transformative imaging device for life science research, digital pathology, fresh tissue diagnostics and eye imaging. MLI® is the most advanced optical absorption imaging device to date. It captures optical absorption from radiative contrast (e.g., autofluorescence), non-radiative relaxation (e.g., temperature, pressure) and scattering channels (indirect optical absorption measurement) simultaneously without contact with the tissue. The ability to generate multiple diagnoses from a single tissue sample and eliminate the need for staining addresses an unmet medical need that has the potential to save lives and reduce costs. For more information, visit www.illumisonics.com.